<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>r10q011.txt
<TEXT>

                  SECURITIES AND EXCHANGE COMMISSION
                        Washington, D.C.  20549

                               Form 10-Q

   X   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
        SECURITIES EXCHANGE ACT OF 1934

           For the quarterly period ended March 31, 2001.

                                   OR

   __  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
        SECURITIES EXCHANGE ACT OF 1934

   For the transition period from _______________to__________________.

                      Commission file number 1-7928

                        BIO-RAD LABORATORIES, INC.
          (Exact name of registrant as specified in its charter)

             Delaware                             94-1381833
   (State or other jurisdiction                (I.R.S. Employer
    of incorporation or organization)           Identification No.)


       1000 Alfred Nobel Drive, Hercules, California 94547
   (Address of principal executive offices)       (Zip Code)

   Registrant's telephone number, including area code (510) 724-7000

                                No Change
   Former name,  former address  and former  fiscal year,  if changed
   since last report.

   Indicate by check whether the registrant (1) has filed all reports
   required to be filed by Section 13 or 15(d) of the Securities
   Exchange Act of 1934 during the preceding 12 months (or for such
   shorter period that the registrant was required to  file such
   reports), and (2) has been  subject  to such  filing
   requirements for the past 90 days.  Yes    X    No  _____

   Indicate the number of shares outstanding of each of the issuer's
   classes of commonstock, as of the latest practicable date--


                                                   Shares Outstanding
         Title of each Class                       at April 30, 2001

         Class A Common Stock,
         Par Value $1.00 per share                 10,051,800

         Class B Common Stock,
         Par Value $1.00 per share                  2,426,328

<PAGE>



                             BIO-RAD LABORATORIES, INC.

                      Condensed Consolidated Statements of Income
                        (In thousands, except per share data)
                                     (Unaudited)
                                                     Three Months Ended
                                                           March 31,
                                                       2001      2000

   NET SALES . . . . . . . . . . . . . . . . . .     $202,668  $185,463

   Cost of goods sold  . . . . . . . . . . . . .       91,318    86,720

   GROSS PROFIT  . . . . . . . . . . . . . . . .      111,350    98,743

   Selling, general and administrative expense .       62,599    62,495

   Product research and development expense  . .       18,428    17,871

   INCOME FROM OPERATIONS  . . . . . . . . . . .       30,323    18,377

   Interest expense  . . . . . . . . . . . . . .       (6,589)   (8,766)

   Other, net  . . . . . . . . . . . . . . . . .      (10,132)   (5,265)

   INCOME BEFORE TAXES . . . . . . . . . . . . .       13,602     4,346

   Provision for income taxes  . . . . . . . . .        5,033     1,391

   NET INCOME  . . . . . . . . . . . . . . . . .     $  8,569  $  2,955
                                                     ========  ========

   Basic earnings per share:
        Net income . . . . . . . . . . . . . . .        $0.70     $0.24
                                                     ========  ========
        Weighted average common shares . . . . .       12,254    12,177
                                                     ========  ========
   Diluted earnings per share:
        Net income . . . . . . . . . . . . . . .        $0.68     $0.24
                                                     ========  ========
        Weighted average common shares                 12,547    12,256
                                                     ========  ========




   The accompanying notes are an integral part of these statements.
                                          1

<PAGE>











                                   BIO-RAD LABORATORIES, INC.
                              Condensed Consolidated Balance Sheets
                                (In thousands, except share data)
  <TABLE>
  <CAPTION>

                                                                March 31,     December 31,
                                                                   2001           2000
                                                                      (Unaudited)
   <S>                                                           <C>            <C>
   ASSETS:
   Cash and cash equivalents  . . . . . . . . . . . . . .        $  9,994       $ 13,954
   Accounts receivable, net . . . . . . . . . . . . . . .         191,792        182,242
   Inventories  . . . . . . . . . . . . . . . . . . . . .         136,713        132,519
   Prepaid expenses, taxes and other current assets . . .          42,044         40,953

      Total current assets  . . . . . . . . . . . . . . .         380,543        369,668

   Net property, plant and equipment  . . . . . . . . . .         118,787        119,032
   Goodwill, net  . . . . . . . . . . . . . . . . . . . .          87,881         90,970
   Other assets . . . . . . . . . . . . . . . . . . . . .          63,668         66,608

        Total assets  . . . . . . . . . . . . . . . . . .        $650,879       $646,278
                                                                 ========       ========
   LIABILITIES AND STOCKHOLDERS' EQUITY:

   Accounts payable . . . . . . . . . . . . . . . . . . .        $ 62,046       $ 62,965
   Accrued payroll and employee benefits  . . . . . . . .          45,290         52,354
   Notes payable and current maturities of long-term debt          17,992         18,146
   Sales, income and other taxes payable  . . . . . . . .          14,312          8,413
   Other current liabilities  . . . . . . . . . . . . . .          51,900         47,430

      Total current liabilities . . . . . . . . . . . . .         191,540        189,308

   Long-term debt, net of current maturities  . . . . . .         202,901        203,360
   Deferred tax liabilities . . . . . . . . . . . . . . .           9,173          8,992

      Total liabilities . . . . . . . . . . . . . . . . .         403,614        401,660

   STOCKHOLDERS' EQUITY:

   Preferred stock, $1.00 par value, 2,300,000 shares
     authorized; none outstanding . . . . . . . . . . . .              --             --

   Class A common stock, $1.00 par value, 15,000,000 shares
     authorized; outstanding - 10,051,800 at March 31, 2001
     and 10,042,200 at December 31, 2000 . . . . . . . . .         10,052         10,042

   Class B common stock, $1.00 par value, 6,000,000 shares
     authorized; outstanding - 2,426,328 at March 31, 2001
     and 2,435,928 at December 31, 2000 . . . . . . . . .           2,426          2,436

   Additional paid-in capital . . . . . . . . . . . . . .          19,120         19,120

   Class A treasury stock, 206,519 shares at March 31, 2001
     and 244,499 shares at December 31, 2000 at cost  . .          (4,574)        (5,415)

   Retained earnings  . . . . . . . . . . . . . . . . . .         240,402        231,821

   Accumulated other comprehensive income:
     Currency translation . . . . . . . . . . . . . . . .         (20,266)       (13,545)

     Net unrealized holding gain on marketable securities             105            159
      Total stockholders' equity  . . . . . . . . . . . .         247,265        244,618

         Total liabilities and stockholders' equity . . .        $650,879       $646,278
                                                                 ========       ========



   The accompanying notes are an integral part of these statements.
 </TABLE>
                                                 2
 <PAGE>


                                  BIO-RAD LABORATORIES, INC.
                        Condensed Consolidated Statements of Cash Flows
                                        (In thousands)
                                          (Unaudited)
<TABLE>
<CAPTION>

                                                                         Three Months Ended
                                                                               March 31,

                                                                          2001         2000
   <S>                                                                  <C>         <C>
   Cash flows from operating activities:
        Cash received from customers . . . . . . . . . . . . .          $183,233    $183,781
        Cash paid to suppliers and employees . . . . . . . . .          (168,730)   (176,672)
        Interest paid. . . . . . . . . . . . . . . . . . . . .           (10,291)     (7,353)
        Income tax payments  . . . . . . . . . . . . . . . . .            (1,265)     (2,676)
        Miscellaneous payments . . . . . . . . . . . . . . . .              (732)     (2,902)

        Net cash provided by (used in) operating activities. .             2,215      (5,822)

   Cash flows from investing activities:
        Capital expenditures, net. . . . . . . . . . . . . . .            (9,278)     (8,318)
        Net sales of marketable securities and investments. . .               62         105
        Foreign currency hedges, net . . . . . . . . . . . . .             1,056       2,330

        Net cash used in investing activities. . . . . . . . .            (8,160)     (5,883)

   Cash flows from financing activities:
         Net repayments under line-of-credit arrangements. . .            (2,825)     (5,009)
         Long-term borrowings. . . . . . . . . . . . . . . . .            45,500     369,251
         Payments on long-term debt. . . . . . . . . . . . . .           (43,113)   (353,047)
         Arrangement and other fees for long-term financing. .                --      (4,500)
         Proceeds from issuance of common stock. . . . . . . .               841         290
         Treasury stock activity, net. . . . . . . . . . . . .                12       1,205

         Net cash provided by financing activities . . . . . .               415       8,190

   Effect of exchange rate changes on cash . . . . . . . . . .             1,570       1,749
   Net decrease in cash and cash equivalents . . . . . . . . .            (3,960)     (1,766)
   Cash and cash equivalents at beginning of period. . . . . .            13,954      17,087
   Cash and cash equivalents at end of period. . . . . . . . .          $  9,994    $ 15,321
                                                                        ========    ========

   Reconciliation of net income to net cash provided by operating activities:

     Net income  . . . . . . . . . . . . . . . . . . . . . . .          $  8,569    $  2,955
     Adjustments to reconcile net income to net cash
       provided by operating activities:
          Depreciation and amortization. . . . . . . . . . . .            10,302      10,688
          Foreign currency hedge transactions, net . . . . . .            (1,056)     (2,330)
          Gains on dispositions of marketable securities . . .               (64)       (304)
          Decrease (increase) in accounts receivable . . . . .           (16,645)      2,910
          Increase in inventories  . . . . . . . . . . . . . .            (7,180)    (10,922)
          Decrease (increase)in other current assets . . . . .            (1,596)        193
          Increase (decrease)in accounts payable and
            other current liabilities  . . . . . . . . . . . .             2,885      (7,502)
          Increase (decrease) in income taxes payable. . . . .             4,210      (1,041)
          Other. . . . . . . . . . . . . . . . . . . . . . . .             2,790        (469)

   Net cash provided by operating activities . . . . . . . . .          $  2,215    $ (5,822)
                                                                        ========    ========
   The accompanying notes are an integral part of these statements.
</TABLE>

                                                  3
<PAGE>

                       BIO-RAD LABORATORIES, INC.

          Notes to Condensed Consolidated Financial Statements
                              (Unaudited)

   1. BASIS OF PRESENTATION

   The accompanying unaudited condensed consolidated financial
   statements of Bio-Rad Laboratories, Inc. ("Bio-Rad" or the
   "Company"), reflect all adjustments which are, in the opinion of
   management, necessary to a fair statement of the results of the
   interim periods presented.  All such adjustments are of a normal
   recurring nature.  The condensed consolidated financial
   statements should be read in conjunction with the notes to the
   consolidated financial statements contained in the Company's
   Annual Report for the year ended December 31, 2000.  Certain
   amounts in the financial statements of the prior year have been
   reclassified to be consistent with the 2001 presentation.

   2. INVENTORIES

   The principal components of inventories are as follows:

                                          March 31,     December 31,
                                            2001           2000
                                               (in thousands)

   Raw materials                          $ 35,109       $ 32,993
   Work in process                          30,349         30,071
   Finished goods                           71,255         69,455

                                          $136,713       $132,519
                                          ========       ========

   3. PROPERTY, PLANT AND EQUIPMENT

   The principal components of property, plant and equipment are as
   follows:

                                          March 31,     December 31,
                                            2001           2000
                                               (in thousands)

   Land and improvements                  $  8,312       $  8,337
   Buildings and leasehold
     improvements                           65,836         66,039
   Equipment                               169,571        180,827
                                           243,719        255,203
   Accumulated depreciation               (124,932)      (136,171)

   Net property, plant and equipment      $118,787       $119,032
                                          ========       ========

   4.   ACQUISITIONS AND DISPOSITIONS

   In July 2000, Accent Semiconductor Technology, Inc. ("ASTI")
   acquired the assets and certain liabilities of the Company's
   semiconductor and optoelectronic metrology business.  The
   proceeds of approximately $36,000 represent $27,000 in cash, an

                                   4

<PAGE>


   $8,000 note receivable due in five years and an 18% passive
   equity interest in ASTI.  The Company used $17,000 of the cash
   proceeds to reduce borrowings on the term loan portion of the
   Senior Credit facility.  The equity interest in ASTI will be held
   as a long-term investment on the cost method.

   In October 1999, the Company acquired Pasteur Sanofi Diagnostics
   S.A., a French corporation, from its shareholders, Sanofi-
   Synthelabo S.A. and Institut Pasteur.  Purchase liabilities
   recorded included approximately $14,000 for severance and other
   employee costs and $4,000 for the consolidation and closure of
   certain leased facilities.  The closure of facilities identified
   by the Company were completed in fiscal 2000, with lease payments
   net of sublease revenues continuing until all contractual
   obligations are met.  As of March 31, 2001, expenses charged
   against these reserves were approximately $12,900 for severance
   and other employee costs and $2,000 for facilities and asset
   related write-offs.

   5.   EARNINGS PER SHARE

   Weighted average shares used for diluted earnings per share
   include the dilutive effect of outstanding stock options of
   293,000 and 79,000 shares, for the three month periods ended
   March 31, 2001 and 2000, respectively.

   Options to purchase 215,000 shares of common stock were
   outstanding during the three month period ended March 31, 2000,
   but were excluded from the computation of diluted earnings per
   share because the exercise price of the options was greater than
   the average market price of the common shares.  There were no
   anti-dilutive shares for the three month period ended March 31,
   200l.

   6.   OTHER INCOME AND EXPENSE

   The components of Other, net were:

                                             Three Months Ended
                                                  March 31,
                                              2001        2000
                                               (in thousands)

   Goodwill amortization                   $(2,021)      $(1,990)
   Non-operating litigation costs, net        (700)         (542)
   Write-down of investment in affiliates   (2,000)           --
   Write-down of spectroscopy
     instrument assets                      (4,500)           --
   Other                                      (911)       (2,733)
   Total Other, net                       $(10,132)      $(5,265)
                                           =======       =======

   In the first quarter of 2001, the Company took a $4,500 non-cash
   pre-tax charge reflecting the potential impact of a non-binding
   letter of intent to sell the spectroscopy instrument business to
   a new owner.  Additionally, the Company took a $2,000 non-cash
   pre-tax charge to adjust the value of an investment based on
   on-going discussions with the investment's management concerning
   its future capital structure.

                                   5

 <PAGE>



   7.   COMPREHENSIVE INCOME

   The components of the Company's total comprehensive income were:

                                             Three Months Ended
                                                  March 31,
                                              2001         2000
                                               (in thousands)

   Net Income                              $ 8,569       $ 2,955

   Currency translation adjustments         (6,721)       (5,812)
   Net unrealized holding gains                  3           463
   Reclassification adjustments for
    gains included in net income               (57)         (217)
   Total comprehensive income (expense)    $ 1,794       $(2,611)
                                           =======       =======

   8.   SEGMENT INFORMATION

   Information regarding industry segments for the three months
   ended March 31, 2001 and 2000 is as follows (in thousands):

                                 Life       Clinical     Analytical
                                Science    Diagnostics   Instruments

   Segment net sales     2001    $92,938    $102,989      $ 7,505
                         2000    $67,731    $100,461      $18,379


   Segment profit(loss)  2001    $19,091     $ 8,122      $  (928)
                         2000    $ 7,133     $ 2,992      $   341


   Inter-segment sales are primarily between Life Science and
   Clinical Diagnostics and are priced to give Life Science a
   representative gross margin.  The following reconciles total
   segment profit to consolidated income before taxes:

                                       Three Months Ended
                                            March 31,
                                        2001         2000
                                          (in thousands)

   Total segment profit               $26,285      $10,466

   Gross profit on inter-segment sales   (384)        (561)
   Net corporate operating, interest
    and other expense not allocated
    to segments                       (10,302)      (3,857)
   Goodwill amortization               (2,021)      (1,990)
   Investment income, net                  24          288

   Consolidated income before taxes   $13,602      $ 4,346
                                      =======      =======



                                   6

 <PAGE>


   Item 2.   Management's  Discussion and Analysis of
             Results of Operations and Financial Condition.

   This discussion should be read in conjunction with the information
   contained both in this report and in the Company's Consolidated
   Financial Statements for the year ended December 31, 2000.

   The following table shows operating income and expense items as a
   percentage of net sales:

                                Three Months Ended   Year Ended
                                     March 31,       December 31,
                                  2001      2000        2000

   Net sales                     100.0     100.0        100.0
    Cost of goods sold            45.1      46.8         47.3
   Gross profit                   54.9      53.2         52.7

   Selling, general and
    administrative                30.8      33.7         34.1

   Product research and
    development                    9.1       9.6          9.4

   Income from operations         15.0       9.9          9.2
                                 =====     =====        =====

   Net income                      4.2       1.6          4.3
                                 =====     =====        =====

   Forward Looking Statements

   Other than statements of historical fact, statements made in this
   report include forward looking statements, such as statements
   with respect to the Company's future financial performance,
   operating results, plans and objectives.  We have based these
   forward looking statements on our current expectations and
   projections about future events.  However, actual results may
   differ materially from those currently anticipated depending on a
   variety of risk factors including among other things: our
   substantial leverage and ability to service our debt; our ability
   to successfully develop and market new products; our reliance on
   and access to necessary intellectual property; competition in and
   government regulation of the industries in which we operate; and
   the monetary policies of various countries.  We undertake no
   obligation to publicly update or revise any forward looking
   statements, whether as a result of new information, future
   events, or otherwise.


             Three Months Ended March 31, 2001 Compared to
                   Three Months Ended March 31, 2000

   Corporate Results - Sales, Margins and Expenses

   Net sales (sales) in the first quarter of 2001 were $202.7
   million compared to $185.5 million in the first quarter of 2000,
   an increase of 9.3%.  Sales increased 37.2% in Life Science and
   2.5% in Clinical Diagnostics.  The growth in Life Science is

                                   7

  <PAGE>





   attributed to a strong demand for the Company's products by
   proteomic and genomic researchers.  Sales growth was especially
   strong in European markets as a result of the Company's BSE
   (Bovine Spongiform Encephalopathy) test used to detect the
   presence of prions linked to the Mad Cow Disease.  Clinical
   Diagnostics growth was provided by products for diabetes
   monitoring, quality controls, blood virus and autoimmune testing.
   On a comparative basis, first quarter sales were adversely
   affected by the strength of the U.S. dollar versus the prior
   period.  Reported growth would increase by 5% for both Life
   Science and Clinical Diagnostics if international sales were
   translated at a constant exchange rate.  Sales in the Analytical
   Instruments segment declined as the Company sold its
   semiconductor instrument product line effective August 1, 2000.

   Consolidated gross margins were 54.9% for the first quarter of
   2001 compared to 53.2% for the first quarter of 2000 and 52.7%
   for all of 2000.  Gross margins improved in Life Science as many
   of the products providing sales growth yield higher margins than
   the segment's overall average.   Clinical Diagnostics margins
   improved due to the cessation of a distributor agreement,
   improved manufacturing overhead absorption and adjustments made
   in the prior year to have the PSD manufacturing sites comply with
   the Company's obsolescence and excess inventory policies.

   Selling, general and administrative expense (SG&A) decreased to
   30.8% of sales in the first quarter of 2001 from 33.7% of sales
   the first quarter of 2000.  SG&A for Life Science increased 14.4%
   as sales grew 37.2%.  Clinical Diagnostics experienced a small
   decline in SG&A expenditures as selling expenditures declined
   mainly in Europe from planned reductions which were part of the
   PSD acquisition, offset by increases in the rest of the world.
   The long-term goal for management remains a consistent gradual
   reduction in SG&A spending as a percent of sales.

   Product research and development expense decreased slightly to
   9.1% as a percentage of sales from 9.6% for the first quarter of
   2000.

   Corporate Results - Non-Operating Items

   Interest expense decreased from the prior year reflecting the
   reduction of debt.  Net other income and expense in the first
   quarter of 2001 includes $6.5 million of non-cash pre-tax expense
   relating to the impact of transactions in negotiation to transfer
   ownership in the Company's spectroscopy instrument business and a
   change in the Company's valuation of an investment based on
   on-going discussions with the investment's management concerning
   its future capital structure.  Net other income and expense in
   the first quarter of 2000 includes a $3.0 million non-recurring
   payment to settle a dispute arising under the terms of an
   engagement letter between the Company and an investment bank.
   Net other income and expense in both years includes net goodwill
   amortization and non-operating legal costs.


                                   8

  <PAGE>





   The Company's effective tax rate rose to 37% for the first
   quarter of 2001 compared to 32% in the first quarter of 2000.
   The increased rate reflects the limitation on the deductibility
   of goodwill amortization associated with the acquisition of PSD,
   the utilization of loss carryforwards and a change in the
   geographical source of taxable income.

   Financial Condition

   The Company, as of March 31, 2001, had available approximately
   $95 million under its principal revolving credit agreement and
   $22 million under various foreign lines of credit.  Cash and cash
   equivalents available were $10.0 million.

   At March 31, 2001, consolidated accounts receivable increased by
   $9.6 million from December 31, 2000.  The increase was due to
   higher sales volume being offset by the declining value of
   European and Japanese currencies as well as an improved mix of
   more consumable sales and less instruments.

   At March 31, 2001, consolidated net inventories increased by $4.2
   million from December 31, 2000. Life Science increased inventory
   levels to meet increased customer demands for its consumable and
   apparatus products.  Clinical Diagnostic inventory levels
   remained flat as the inventory increase for the quality control
   product lines was offset by foreign held inventory declining due
   to currency translation.  Inventory for the Clinical Diagnostics
   quality controls business is characterized by long lead times and
   large infrequent batch production which is necessary to meet
   customers requirements.  Bio-Rad management regularly reviews
   inventory valuation for excess, obsolete and slow-moving
   products.

   Net capital expenditures totaled $9.3 million for the first three
   months of 2001 compared to $8.3 million for the same period of 2000.
   Capital expenditures for the quarter are principally for reagent
   rental equipment placed with Clinical Diagnostic customers who then
   commit to purchasing the Company's diagnostic reagents for use.  The
   remaining expenditures represent the Company's investment in data
   communication and business systems to standardize and integrate its
   new acquisition and production equipment.

   The Company now believes that continued growth will cause it to
   require additional space in Northern California for manufacturing,
   laboratory and general office use.  Management is currently
   reviewing its space requirements and financing alternatives that
   could result in increased capital expenditures later in 2001 and
   beyond.

   The Company has determined that the sale or disposal of certain
   remaining portions of the Analytical Instruments segment is
   appropriate.  The Company took a $4.5 million non-cash charge in the
   first quarter of 2001 reflecting the potential impact of a non-
   binding letter of intent to sell the spectroscopy instrument
   business to a new owner.  We cannot guarantee, however, that the

                                     9

  <PAGE>





   Company will be successful in completing this transaction. Should it
   not happen, the Company will immediately pursue other alternatives.

   Euro - A New European Currency

   On January 1, 1999, certain member countries of the European Union
   began to fix the conversion rates between their national currencies
   and a common currency, the "Euro."   Over the period January 1, 1999
   through January 1, 2002 participating countries will gradually
   transition from their national currencies to the Euro.

   This transition will have business implications including the need
   to adjust internal systems to accommodate the Euro and cross-border
   price transparency.  A group of Corporate and European managers have
   been assigned the task of preparing and accommodating the changes
   required to continue to do business in the European Union.  The
   Company has not experienced to date nor does it expect that these
   changes will have a material impact on operations, financial
   position or liquidity.  There will be increased competitive
   pressures as a result of the change, and marketing strategies will
   need to be continuously evaluated until the transition is complete.
   As a result of competitive forces and government regulations, the
   Company cannot guarantee that all problems will be foreseen and
   remediated, and that no material disruption will occur.

   New Financial Accounting Standards

   In June 1998, the Financial Accounting Standards Board issued
   Statement of Financial Accounting Standards (SFAS) No. 133,
   "Accounting for Derivative Instruments and Hedging Activities"
   effective for fiscal years beginning after June 15, 2000.  This
   statement establishes accounting and reporting standards
   requiring companies to record all derivatives on the balance
   sheet as either assets or liabilities and measure those
   instruments at fair value.  The manner in which companies are to
   record gains or losses resulting from changes in the values of
   those derivatives depends on the use of the derivative and
   whether it qualifies for hedge accounting.  The Company adopted
   SFAS 133 and subsequent amendments as of the first day of fiscal
   year 2001 and will currently not seek hedge accounting treatment,
   instead recording the value adjustment to derivative instruments
   through earnings.

   Item 3.   Quantitative and Qualitative Disclosures
             About Market Risk

   During the three months ended March 31, 2001, there have been no
   material changes from the disclosures about market risk provided
   in the Company's Annual Report on Form 10-K for the year ended
   December 31, 2000.



                                   10

    <PAGE>





   PART II.  OTHER INFORMATION

   Item 4.  Submission of Matters to a Vote of Security Holders.

   At the Company's annual meeting of stockholders on April 24,
   2001, the following individuals were reelected to the Board of
   Directors:

                              Class of
                            Common Stock        Votes           Votes
                            Elected From         For           Withheld

   James J. Bennett           Class B       2,318,267              558
   Albert J. Hillman          Class A       6,455,352          814,231
   Philip L. Padou            Class A       6,514,752          754,831
   Alice N. Schwartz          Class B       2,318,267              558
   David Schwartz             Class B       2,318,267              558
   Norman Schwartz            Class B       2,318,267              558

   The following proposals were approved at the Company's annual meeting:

                            Votes       Votes                     Broker
                             For       Against    Abstentions    Non-Votes

   Ratification of
     Arthur Andersen LLP
     as the Company's
     independent auditors 3,044,280     1,222           282          --
   Stock Option Plan
     Amendment            2,615,611   103,449         6,046     320,677

   The foregoing matters are described in detail on pages 5, 6, 16,
   17 and 18 of the Company's definitive Proxy Statement dated
   April 2, 2001, filed with the Securities and Exchange Commission
   and incorporated herein by reference.

   Item 6.  Exhibits and Reports on Form 8-K.

   (a)  Exhibits

   The following documents are filed as part of this report:

   Exhibit No.

   22.1      Proxy Statement dated April 2, 2001, pages 5, 6, 16, 17
             and 18, (definitive form filed April 4, 2001, and
             incorporated by reference).

   (b)  Reports on Form 8-K

   There were no reports on Form 8-K for the quarter ended
   March 31, 2001.

                                   11
   <PAGE>

                                SIGNATURES


       Pursuant to the  requirements of the  Securities Exchange Act  of
       1934, the registrant  has duly caused this report to be signed on
       its behalf by the undersigned thereto duly authorized.

                                     BIO-RAD LABORATORIES, INC.
                                           (Registrant)



       Date:  May 14, 2001      /s/ T. C. Chesterman
                                T. C. Chesterman, Vice President,
                                     Chief Financial Officer



       Date:  May 14, 2001      /s/ James R. Stark
                                James R. Stark, Corporate Controller






























                                          12
<PAGE>
</TEXT>
</DOCUMENT>
